Scholarlink

Background <p>Cirrhosis is a major global health burden, often requiring ICU admission due to complications. Acetaminophen (APAP) is frequently used for pain and fever management in critically ill patients, but its safety in cirrhotic patients remains uncertain.</p> Aims <p>To evaluate the association between early APAP use and mortality outcomes in ICU patients with cirrhosis.</p> Methods <p>This retrospective cohort study used the MIMIC-IV database. Adult cirrhotic patients were divided into two groups based on whether they received APAP within 24&#xa0;h of ICU admission. The primary outcome was 28-day ICU mortality; secondary outcomes included 7-day, 60-day, in-hospital, and overall ICU mortality. Inverse probability weighting (IPW) was used to adjust for confounders.</p> Results <p>After IPW adjustment, early APAP use was significantly associated with higher 28-day ICU mortality (HR: 1.70, 95% CI: 1.26–2.3), and elevated risks for all secondary outcomes. Subgroup analyses indicated higher mortality risks in patients with cancer, AKI and sepsis. Total bilirubin levels were identified as a potential predictor of mortality risk.</p> Conclusions <p>Early APAP administration in critically ill cirrhotic patients is associated with increased mortality. These findings underscore the need for caution when prescribing APAP in this high-risk population and highlight the importance of further prospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early acetaminophen administration and mortality outcomes in critically ill patients with cirrhosis: a retrospective analysis from the MIMIC-IV database

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月16日

查看全文
  • Xiao-fei Fan,
  • Shao-kang Xu,
  • Shen-ao Fu,
  • Xuan He,
  • Jia-kai Fang,
  • Wen Gao,
  • Na Guo

摘要

Background

Cirrhosis is a major global health burden, often requiring ICU admission due to complications. Acetaminophen (APAP) is frequently used for pain and fever management in critically ill patients, but its safety in cirrhotic patients remains uncertain.

Aims

To evaluate the association between early APAP use and mortality outcomes in ICU patients with cirrhosis.

Methods

This retrospective cohort study used the MIMIC-IV database. Adult cirrhotic patients were divided into two groups based on whether they received APAP within 24 h of ICU admission. The primary outcome was 28-day ICU mortality; secondary outcomes included 7-day, 60-day, in-hospital, and overall ICU mortality. Inverse probability weighting (IPW) was used to adjust for confounders.

Results

After IPW adjustment, early APAP use was significantly associated with higher 28-day ICU mortality (HR: 1.70, 95% CI: 1.26–2.3), and elevated risks for all secondary outcomes. Subgroup analyses indicated higher mortality risks in patients with cancer, AKI and sepsis. Total bilirubin levels were identified as a potential predictor of mortality risk.

Conclusions

Early APAP administration in critically ill cirrhotic patients is associated with increased mortality. These findings underscore the need for caution when prescribing APAP in this high-risk population and highlight the importance of further prospective validation.